The NCBI article 'La Crosse Encephalitis' defines La Crosse encephalitis as an arboviral illness spread by mosquitoes. The condition was initially noticed by doctors in the 1960s in the Wisconsin county of La Crosse, hence the disease's name. It was noticed that children experience this encephalitis mostly in the summer.
The highest documented incidence is paediatric arboviral encephalitis.
The Eastern treehole mosquito, also known as Aedes triseriatus, which carries the La Crosse virus, is a member of the Bunyaviridae family, belongs to the California serogroup, and is responsible for the disease transmission. The primary host and vector for the La Crosse virus are known to be Aedes mosquito.
Aedes albopictus and Aedes japonicus, two additional mosquito species, have also been identified as vectors in the transmission of the La Crosse virus and are probably beginning to play a prominent role in the spread of the virus in endemic areas.
The Aedes triseriatus mosquito, also known as the treehole mosquito, transmits the La Crosse virus, which causes the viral disease known as La Crosse encephalitis.
Both vertical (from mother to child) and horizontal (from person to person) transmission are part of the cycle of transmission of the virus.
According to NCBI, infected humans act as dead-end hosts as they do not reach the level to infect feeding mosquitoes.
Vertical transmission happens from the female adult mosquito to her young, who can then spread the infection to humans and other mammals.
Most people with La Crosse (LAC) virus do not exhibit any symptoms. The incubation period (time between an infected mosquito bite and first showing symptoms) for persons with symptoms is between 5 and 15 days.
Common symptoms are
Children under the age of 16 are more likely than adults to experience severe illness.
This can manifest as
Brain infections can also arise due to the LAC virus (encephalitis).
Less common signs include,
After a severe illness, recovery takes time, and effects on the central nervous system may last for some time. Recurrent seizures and cognitive or behavioural problems are common. Most patients tend to recover, and mortality is rare.
The LAC virus can be transmitted to people by the bite of an infected mosquito. However, humans rarely acquire blood levels of LACV that infect actively feeding mosquitoes. Therefore, people are regarded as dead-end or accidental hosts for LACV. Any individual who contracts LACV can become unwell, although those between the ages of 5 and 15 are more likely than older adults to have a severe neurological illness from LACV infection.
Consulting a healthcare professional is essential for noticing any LAC virus disease symptoms.
Medical professionals determine whether a patient has the LAC virus by
The following are typical physical examination results for La Crosse encephalitis.
The patient is requested for a complete and detailed history if possible. Fever, headache, nausea, vomiting, seizures, altered state of mind and fatigue are typical signs of La Crosse encephalitis that patients must note.
For La Crosse encephalitis, laboratory testing is the preferred technique of diagnosis. The following laboratory findings support a diagnosis of La Crosse encephalitis.
The LACV disease has no specific treatment. Currently, no effective antiviral medications are available, and antibiotics are ineffective against viruses. Supportive care, which may include hospitalisation, respiratory assistance, intravenous (IV) fluids and the avoidance of secondary infections, helps treat severe illnesses.
According to an NCBI article titled 'La Crosse Encephalitis', Ribavirin has an off-label application in La Crosse encephalitis. It has been linked to in vitro reduction of RNA virus replication. Although its efficacy is frequently questioned, intravenous ribavirin likely targets the RNA-dependent RNA polymerase.
Prior research on paediatric patients revealed that ribavirin adequately penetrated the Cerebrospinal Fluid (CSF) and reached levels close to 70% of plasma. More recent clinical studies do not support these results.
Due to significantly lower CSF levels than intravenous dosing, oral Ribavirin for La Crosse encephalitis is not regarded as a viable alternative. In vitro, La Crosse virus replication was inhibited by relatively low amounts of ribavirin (0.3 umol/L).
Using analgesics, taking adequate rest and proper hydration help treat milder types of conditions that manifest with fevers and headaches. When a patient has acute encephalopathy, it is okay to start intravenous acyclovir treatment until HSV encephalitis has been ruled out.
Anti-seizure drugs may be necessary to control people who tend to have seizures. Patients with epilepsy may want to consult a doctor about taking anti-seizure medications for a long time.
It may be necessary to do mechanical intubation and airway treatment for patients who have a coma with respiratory compromise. Occasionally, La Crosse encephalitis patients with hyponatremia may benefit from central venous pressure monitoring to keep their intravascular volume normal.
There are numerous issues connected to La Crosse encephalitis. Acute complications could be mild and self-limiting, or they could cause a critical illness that could be fatal. La Crosse encephalitis can also cause long-term effects in addition to acute symptoms.
Acute complications
Chronic complications
Protecting from mosquito bites is the best preventive method against LACV.
Conclusion
La Crosse encephalitis is a mild infection occurring in the central nervous system. Typically, mosquitoes spread the La Crosse encephalitis virus to the human host. One contracts the La Crosse encephalitis virus by being bitten by an infected mosquito, primarily an Aedes triseriatus mosquito.
The age range of newborns and children who contract the La Crosse encephalitis virus is between six months and fifteen years. The La Crosse encephalitis virus seldom returns and often clears up in 1 to 2 weeks.
Fewer than 1% of cases are fatal. Laboratory testing is the preferred way for diagnosing the La Crosse encephalitis virus. The cornerstone of therapy for the La Crosse encephalitis virus is supportive care.
We’re Star Health. We offer the coverage that’s designed to help keep you healthy. It's the care that comes to you, and stays with you.